News ArchivesRead News
New research program tackles Parkinson’s disease
Tuesday December 19, 2006
December 14, 2006(University of Wisconsin System) - A new research collaboration at the University of Wisconsin-Madison aims to move promising new therapies for Parkinsons disease from primates to patients.
Based at the Wisconsin National Primate Research Center and named the Preclinical Parkinsons Disease Research Program, the collaboration became official in November. Joseph Kemnitz, professor of physiology and Primate Center director, is the programs executive director. Renowned Parkinsons disease expert Marina Emborg, senior scientist at the Primate Center and in the department of anatomy, is scientific director. "Our goal is to hasten discoveries that will lead to new therapies for Parkinsons disease, with an emphasis on cell and gene-based therapies," says Kemnitz.
Through the new program, the Primate Center is poised to become the countrys centralized resource for Parkinsons disease research using nonhuman primate models, especially macaques, Kemnitz says. Program collaborators and funding agencies that will help develop the necessary laboratory and animal resources at the Primate Center include WinCon, a biotechnology company in Nanning, Guangxi, China; researchers at the Beijing Institute of Geriatrics, and an anonymous foundation.
"Macaques are regarded by many as the most useful model for Parkinsons research," Kemnitz says. "These collaborators chose the Wisconsin National Primate Research Center because we have a well established infrastructure for conducting research using nonhuman primates, and UW-Madison has a broad range of expertise directly relevant to this program."
That expertise lies in the UW-Madisons renowned capabilities in brain imaging technology, stem cell biology and clinical biomanufacturing. Researchers from the Primate Center, Waisman Center, School of Medicine and Public Health, School of Pharmacy, and other campus entities are already developing promising Parkinsons therapies based on embryonic stem cell derivations, trophic (nutritive) factors, compounds called thiazolidenediones, deep brain stimulation and other treatment avenues.
"Were committed to finding a cure for Parkinsons disease," Emborg says.
Recent NewsMar 27 - March 27, 2018 News Update
Mar 20 - March 20, 2018 News Update
Mar 13 - March 13, 2018 News Update
Mar 6 - March 6, 2018 News Update
Feb 27 - February 27, 2018 News Update
Feb 20 - February 20, 2018 News Update
Feb 13 - February 13, 2018 News Update
Feb 6 - February 6, 2018 News Update
Jan 30 - January 30, 2018 News Update
Jan 23 - January 23, 2018 News Update
Jan 16 - January 16, 2018 News Update
Jan 9 - January 9, 2018 News Update
Jan 2 - January 2, 2018 News Update
Dec 26 - December 26, 2017 News Update
Dec 19 - December 19, 2017 News Update
Dec 8 - New technique scours the genome for genes that combat disease
Dec 8 - Restless sleep may be an early sign of Parkinson's, dementia
Dec 1 - Defects in cell's 'waste disposal system' linked to Parkinson's
Dec 1 - Dual virtual reality/treadmill exercises promote brain plasticity in Parkinson's patients
Nov 17 - 'Moving Day' participant is not letting young-onset Parkinson's disease stop him